These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37802462)

  • 1. An exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users.
    Diamond B; Sheeder J; Lazorwitz A
    Contraception; 2024 Jan; 129():110298. PubMed ID: 37802462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study.
    Lazorwitz A; Sheeder J; Teal S
    Contraception; 2023 Jul; 123():110035. PubMed ID: 36997081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users.
    Lazorwitz A; Aquilante CL; Sheeder J; Guiahi M; Teal S
    Contraception; 2019 Jul; 100(1):37-41. PubMed ID: 30980827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
    Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
    Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant.
    Clure C; Sheeder J; Lazorwitz A
    Contraception; 2024 Jul; 135():110442. PubMed ID: 38552822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users.
    Lazorwitz A; Sheeder J; Teal S
    Eur J Contracept Reprod Health Care; 2021 Aug; 26(4):323-325. PubMed ID: 33596152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period.
    Lazorwitz A; Sheeder J; Teal S
    Contraception; 2022 Apr; 108():65-68. PubMed ID: 34973207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
    Bahamondes L; Brache V; Ali M; Habib N;
    Contraception; 2018 Sep; 98(3):181-187. PubMed ID: 29777663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing Weight Status in Adolescent and Young Adult Users of the Etonogestrel Contraceptive Implant.
    Romano ME; Braun-Courville DK
    J Pediatr Adolesc Gynecol; 2019 Aug; 32(4):409-414. PubMed ID: 30928532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users.
    Lazorwitz A; Pena M; Sheeder J; Teal S
    Obstet Gynecol; 2022 Apr; 139(4):579-587. PubMed ID: 35594123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
    McNicholas C; Swor E; Wan L; Peipert JF
    Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users.
    Lazorwitz A; Dindinger E; Harrison M; Aquilante CL; Sheeder J; Teal S
    Contraception; 2020 Sep; 102(3):180-185. PubMed ID: 32407811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users.
    Lazorwitz A; Seale R; Davis A; Guiahi M
    Contraception; 2020 Jul; 102(1):58-60. PubMed ID: 32325076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users.
    Lazorwitz A; Aquilante CL; Dindinger E; Harrison M; Sheeder J; Teal S
    Obstet Gynecol; 2019 Oct; 134(4):807-813. PubMed ID: 31503152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users.
    Lazorwitz A; Davis A; Swartz M; Guiahi M
    Contraception; 2017 Jun; 95(6):571-577. PubMed ID: 28288788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight change at 12 months in users of three progestin-only contraceptive methods.
    Vickery Z; Madden T; Zhao Q; Secura GM; Allsworth JE; Peipert JF
    Contraception; 2013 Oct; 88(4):503-8. PubMed ID: 23582238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective pilot study to assess the impact of the etonogestrel implant on postpartum depression.
    Ross CM; Hammond C; Ralph JA; Balmert LC; Wisner KL; Kiley JW
    Eur J Contracept Reprod Health Care; 2021 Apr; 26(2):98-104. PubMed ID: 33164593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant.
    Modesto W; Dal Ava N; Monteiro I; Bahamondes L
    Arch Gynecol Obstet; 2015 Dec; 292(6):1387-91. PubMed ID: 26088190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of postpartum etonogestrel-releasing implant insertion and bleeding patterns, weight change, 12-month continuation and satisfaction rates: a randomized controlled trial.
    Vieira CS; de Nadai MN; de Melo Pereira do Carmo LS; Braga GC; Infante BF; Stifani BM; Ferriani RA; Quintana SM
    Contraception; 2019 Oct; 100(4):258-263. PubMed ID: 31145885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.